Article thumbnail
Location of Repository

ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation

By Georgios Kitsios and Elias Zintzaras
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2700093
Provided by: PubMed Central

Suggested articles

Citations

  1. (2003). A: Angiotensin I-converting enzyme (ACE) inhibitors and restenosis after coronary artery stenting in patients with the DD genotype of the ACE gene.
  2. (2004). A: Association study of the I/D polymorphism and plasma angiotensin-converting enzyme (ACE) as risk factors for stent restenosis. Clin Sci (Lond)
  3. (2004). AdA: Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis
  4. (1995). AJ: Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease.
  5. (1996). Amouyel P: ACE polymorphism, a genetic predictor of occlusion after coronary angioplasty.
  6. (1998). Amouyel P: Dual determination of angiotensin-converting enzyme and angiotensinII type 1 receptor genotypes as predictors of restenosis after coronary angioplasty.
  7. (2001). Amouyel P: Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Lancet
  8. (2002). Angiotensin converting enzyme insertion or deletion polymorphism and coronary restenosis: meta-analysis of 16 studies. BMJ
  9. (1997). Angiotensin-converting enzyme gene polymorphism and cardiovascular endocrine system in coronary angiography patients. Jpn Heart J
  10. (1996). Angiotensin-converting enzyme insertion/ deletion polymorphism and restenosis after coronary angioplasty in unstable angina pectoris.
  11. (2008). Angiotensin-converting enzyme insertion/deletion gene polymorphic variant as a marker of coronary artery disease: a meta-analysis. Arch Intern Med
  12. (2002). Angiotensinogen M235T gene polymorphism and recurrent restenosis after repeated percutaneous transluminal coronary angiography. Clin Sci (Lond)
  13. (2004). Ardissino D: Angiotensin-converting enzyme insertion/deletion polymorphism and risk of restenosis after directional coronary atherectomy followed by stent implantation. Thromb Haemost
  14. (2000). Assessing the cost-effectiveness of pharmacogenomics.
  15. (2003). AV: DD ACE gene polymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial. Heart
  16. (1993). BK: Mistyping ACE heterozygotes.
  17. (2005). Bozdemir V: The relationship between angiotensin converting enzyme gene polymorphism, coronary artery disease, and stent restenosis: the role of angiotensin converting enzyme inhibitors in stent restenosis in patients with diabetes mellitus. Int Heart J
  18. (2005). Cam N: Influence of angiotensin converting enzyme insertion/deletion polymorphism on long-term total graft occlusion after coronary artery bypass surgery. Heart Surg Forum
  19. (2001). Cardon LR: Trans-ethnic fine mapping of a quantitative trait locus for circulating angiotensin I-converting enzyme (ACE). Hum Mol Genet
  20. (2005). Cavallari LH: Cardiovascular pharmacogenomics. Exp Physiol
  21. (2002). Cho SY: Renin-angiotensin-aldosterone system (RAAS) gene polymorphism as a risk factor of coronary in-stent restenosis. Yonsei Med J
  22. (2007). chronic angina focused update of the ACC/ AHA
  23. (1995). CL: Are Asian coronary arteries smaller than Caucasian? A study on angiographic coronary artery size estimation during life.
  24. (2000). CM: Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.
  25. (2008). Collins R: SLCO1B1 variants and statin-induced myopathy – a genomewide study.
  26. (2002). Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA
  27. (1999). D allele of the angiotensin-converting enzyme gene is a risk factor for secondary cardiac events after myocardial infarction.
  28. (2004). de Boer A: Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting betahydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics
  29. (2002). der: A metaanalysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias. Am Heart J
  30. (2008). DL: Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet
  31. (1997). Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction. Coron Artery Dis
  32. (2001). E: The platelet Pl(A2) and angiotensinconverting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction.
  33. (2002). Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. Hum Mol Genet
  34. (2004). Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation
  35. (2006). Fagard R: The CAREGENE study: ACE gene I/D polymorphism and effect of physical training on aerobic power in coronary artery disease. Heart
  36. (2001). Fernandez-Cruz A: Ace D/I polymorphism and incidence of post-PTCA restenosis: a prospective, angiography-based evaluation. Hypertension
  37. (2001). Funnel plots for detecting bias in metaanalysis: guidelines on choice of axis.
  38. (1997). Gardemann A: The expression of angiotensin-I converting enzyme in human atherosclerotic plaques is not related to the deletion/ insertion polymorphism but to the risk of restenosis after coronary interventions. Atherosclerosis
  39. (2000). Gensini GF: Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients.
  40. (2004). Gilst WH: Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. J Renin Angiotensin Aldosterone Syst
  41. (1995). H: Enhanced predictability of myocardial infarction in Japanese by combined genotype analysis. Hypertension
  42. (1995). Humphries SE: Angiotensin converting enzyme gene polymorphism and the course of angiographically defined coronary artery disease. Atherosclerosis
  43. (2002). Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol
  44. (2006). Kitsios G: Identification of chromosomal regions linked to premature myocardial infarction: a meta-analysis of whole-genome searches.
  45. (2002). Kohno N: Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention. Atherosclerosis
  46. (2002). Lindpaintner K: A prospective evaluation of the angiotensin-converting enzyme D/ I polymorphism and left ventricular remodeling in the 'Healing and Early Afterload Reducing Therapy' study. Clin Genet
  47. (2001). Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure.
  48. (1993). Ogihara T: A potent genetic risk factor for restenosis. Nat Genet
  49. (1999). Ogihara T: Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty. Angiology
  50. (2002). OPTICUS ACE Substudy: Angiotensin-converting enzyme insertion/ deletion polymorphism does not influence the restenosis rate after coronary stent implantation. Cardiology
  51. (2000). Oral D: Relation between the insertion/ deletion polymorphism of the angiotensin I converting enzyme gene and restenosis after coronary stenting. J Cardiovasc Risk
  52. (2003). Outcome following percutaneous coronary intervention: not, so far, in our genes. Heart
  53. (2007). Ozcelik C: Recurrent in-stent restenosis is not associated with the angiotensin-converting enzyme D/I, angiotensinogen Thr174Met and Met235Thr, and the angiotensin-II receptor 1 A1166C polymorphism.
  54. (2003). PROGRESS Collaborative Group: The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension
  55. (2003). Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention. Heart
  56. (2007). Psaty BM: Renin-angiotensin system haplotypes and the risk of myocardial infarction and stroke in pharmacologically treated hypertensive patients.
  57. (2000). Quyyumi AA: Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation
  58. (2001). R: A chymase gene variant is associated with atherosclerosis in venous coronary artery bypass grafts. Coron Artery Dis
  59. (1999). Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up.
  60. (2001). Reiber JH: Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors.
  61. (2002). Rettig R: Angiotensin I-converting enzyme insertion/deletion polymorphism and cardiac mortality and morbidity after coronary artery bypass graft surgery. Chest
  62. (2005). RK: Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function. Heart
  63. (1995). RR: Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty. Circulation
  64. (2001). S: The D-allele of the ACE polymorphism is related to increased QT dispersion in 609 patients after myocardial infarction. Eur Heart J
  65. (2001). S: The DD genotype of angiotensin converting enzyme polymorphism is a risk factor for coronary artery disease and coronary stent restenosis in Japanese patients.
  66. (2007). Schömig A: Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
  67. (2000). Schomig A: Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. Circulation
  68. (2008). Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches.
  69. (2002). T: Quinapril prevents restenosis after coronary stenting in patients with angiotensin-converting enzyme D allele. Circ J
  70. (2005). Takak i H, Iw ai N, Nonogi H, Goto Y: Angiotensin-converting enzyme genotype is not associated with exercise capacity or the training effect of cardiac rehabilitation in patients after acute myocardial infarction. Circ J
  71. (2007). Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts,
  72. (2000). The angiotensinogen gene 235T variant is associated with an increased risk of restenosis after percutaneous transluminal coronary angioplasty. Clin Sci (Lond)
  73. (2002). The endothelial nitric oxide synthase (Glu298Asp and -786T>C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J
  74. (2001). Timmis AD: Angiotensin-converting enzyme inhibition is associated with reduced troponin release in nonST-elevation acute coronary syndromes.
  75. (2007). Topol EJ: Future use of genomics in coronary artery disease.
  76. (2002). Townend JN: The angiotensin-converting enzyme gene I/D polymorphism and heart rate variability following acute myocardial infarction. Clin Auton Res
  77. (2003). Uslenghi E: Effect of angiotensin-converting enzyme inhibition on restenosis after coronary stenting.
  78. (1996). Woods KL: Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of and prognosis after myocardial infarction.
  79. (2004). Writing Committee Members, Anbe

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.